



HAL
open science

Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma

Camille Jubelin, Javier Munoz-Garcia, Denis Cochonneau, Emilie Moranton, Marie Françoise Heymann, Dominique Heymann

► **To cite this version:**

Camille Jubelin, Javier Munoz-Garcia, Denis Cochonneau, Emilie Moranton, Marie Françoise Heymann, et al.. Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma. Cancer Drug Resistance, 2022, 5, 10.20517/cdr.2021.130 . inserm-03550410

HAL Id: inserm-03550410

<https://inserm.hal.science/inserm-03550410>

Submitted on 1 Feb 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Review**

2 **Biological evidence of cancer stem-like cells and recurrent disease**
3 **in osteosarcoma**

4 **Camille Jubelin^{1,2,3}, Javier Muñoz-Garcia², Denis Cochonneau², Emilie Moranton²,**
5 **Marie-Françoise Heymann², Dominique Heymann^{1,2,4}**

6
7 ¹ *Nantes Université, CNRS, US2B, UMR 6286, F-44000 Nantes, France*

8 ² *Institut de Cancérologie de l'Ouest, "Tumor Heterogeneity and Precision Medicine" Laboratory, Saint-Herblain,*
9 *France*

10 ³ *Atlantic Bone Screen, Saint-Herblain, France*

11 ⁴ *University of Sheffield, Department of Oncology and Metabolism, Medical School, Sheffield, UK*
12

13 **Correspondence to:** Prof. Dominique Heymann, Institut de Cancérologie de l'Ouest, Blvd Jacques Monod, 44805
14 Saint-Herblain, France; Email: dominique.heyman@univ-nantes.fr; ORCID: 0000-0001-7777-0669

15 Received: 01st December 2021

16 **Abstract**

17 Sarcomas are a large family of cancers originating in the mesenchyme. Composed of more than 100
18 histological subtypes, soft tissue and bone sarcomas remain clinically challenging, particularly in
19 children and adolescents in whom sarcomas are the second most common malignant entities.
20 Osteosarcoma is the main primary bone tumor in adolescents and young adults, and is characterized by a
21 high propensity to induce distant metastatic foci and to become multi-drug resistant. The innate and
22 acquired resistance of osteosarcoma can be explained by high histological heterogeneity and
23 genetic/molecular diversity. In the last decade, the notion of cancer stem-like cells (CSCs) has emerged.
24 This subset of cancer cells has been linked to drug resistance properties, recurrence of the disease, and
25 finally therapeutic failure. Although CSCs remain controversial, many elements are in favor of them
26 playing a role in the development of the drug resistance profile. The present review gives a brief overview
27 of the most recent biological evidence of the presence of CSCs in osteosarcomas and their role in the drug
28 resistance profile of these rare oncological entities. Their use as promising therapeutic targets will be
29 discussed.

30 **Keywords:** Cancer stem cells, bone sarcoma, soft tissue sarcoma, drug resistance, tumor
31 microenvironment, recurrent disease, residual disease

32 **INTRODUCTION**

33 Sarcomas are composed of highly heterogeneous soft tissue and bone oncological entities that are
34 members of the mesenchymal tumor family^[1,2]. Osteosarcoma is the main bone sarcoma, with high
35 prevalence in adolescents and young adults. Two peaks of incidence are described in the literature, a main
36 peak around 18 years and a second, in the 6th decade, more frequently diagnosed in patients following
37 Paget's disease or radiotherapy, and referred to as secondary osteosarcomas^[2-4]. The conventional



© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

38 therapeutic regimen for osteosarcoma is based on a sequential approach combining surgery and
39 neoadjuvant and adjuvant polychemotherapies^[5]. Considered to be radioresistant, radiotherapy is
40 nevertheless part of the therapeutic arsenal, proposed in osteosarcomas for which the surgical procedure is
41 delicate, such as tumors in high-risk locations, and can be used for better local control of the tumor^[6].
42 Unfortunately, the therapeutic response in osteosarcoma patients has not improved in the last 4 decades,
43 with an overall survival rate of around 70% after 5 years for localized disease. This rate drops
44 dramatically to 30% when lung metastases can be detected^[7].

45 As described in other types of cancer, osteosarcoma evolves under the pressure of random mutational
46 changes^[8,9], with preferential clonal proliferation and epigenetic modifications^[10-13] within the clonal
47 population, leading to genetic instability, high genetic diversity, and high tumor heterogeneity^[13,14].
48 Therapeutic failure is frequently attributed to this intratumoral heterogeneity, and more specifically to the
49 emergence of oligoclonal tumor cells capable of evading the therapeutic drugs. From this observation, has
50 emerged the concept of CSCs, in reference to embryonic stem (ES) cells. CSCs express transcription
51 factors (e.g. Nanog, Oct4, Sox2) initially detected in ES cells, and exhibit pluripotent differentiation
52 properties into various functional cells able to reconstitute the complete tumor mass. The tumor-initiating
53 cells, the CSCs, have been described as tumor cells capable of reproducing all features of the initial tumor
54 mass, and have been associated with tumor recurrence, propagation, and drug resistance^[15-18].
55 Unfortunately, long-term relapse in patients considered clinically disease-free is observed in numerous
56 cancers, including osteosarcoma^[19,20]. Minimal residual disease is defined as malignant cells that are
57 resistant to treatment, and that remain in patients after remission, leading to relapse and metastasis.
58 Minimal residual disease is composed of drug-resistant tumor cells and is presented dynamically as
59 persister/dormant/quiescent/cancer cells in residual tumors, such as circulating tumor cells in peripheral
60 blood, and disseminated tumor cells in bone marrow and other metastatic sites^[13-15, 21]. In this context,
61 tumor recurrence may be related to the persistence of CSCs. More and more evidence highlights the
62 existence of CSCs in osteosarcomas, although their real contribution to pathogenesis remains speculative.
63 The present review aims to give a brief overview of the most recent knowledge available on CSCs in
64 osteosarcoma and their potential clinical interest as new therapeutic targets.

65

66 **PROPERTIES OF CANCER STEM-LIKE CELLS IN OSTEOSARCOMA AND** 67 **BIOLOGICAL *IN VIVO* EVIDENCE**

68 Around 5% of osteosarcoma patients develop local recurrence of their disease between 6 and 28 months
69 after their first line of treatment and disease-free survival of up to 12 years is usually observed in 46% of
70 patients^[22]. A large series confirmed a relatively low rate of local recurrence of high-grade osteosarcoma in
71 contrast to the relapse disease associated with lung metastases^[23,24]. In 2010, Perrot *et al.* described local
72 recurrence with metastatic foci in patients with telangiectatic osteosarcoma of the humerus after 13 years
73 of complete remission^[20]. The local recurrence exhibited the same histological subtype as the initial tumor
74 and was observed at the injection site of autologous fat grafts that had been performed 18 months before
75 the recurrence for plastic surgery. More recently, Pennati *et al.* studied a series of autologous fat grafts in
76 sarcomas and did not exclude an increased risk of local recurrence after the fat grafting procedure^[25].
77 These clinical cases raise the question of the persistence of cancer cells that remain quiescent at the
78 primary tumor site during the remission phase and are reactivated by alteration to their local
79 microenvironment. Interestingly, in 2018, Le Nail *et al.* identified osteosarcoma cells with CSC
80 properties from high grade osteosarcoma samples^[26]. Of the isolated cells, two showed a high ability to

81 form spheroids and even though they were not tumorigenic, these cells supported tumor growth when
82 they were co-inoculated with human osteosarcoma cell lines in immunodeficient mice.

83

84 **Table 1: Biological characteristics and functional properties of CSCs identified in human**
85 **osteosarcoma**

Biomarkers studied	Biological properties	Models	Reference
CD24	<ul style="list-style-type: none"> - Sphere formation - Expression of stemness markers (Oct4, Nanog, Sox2, BMI1) - Properties of tumor-initiating cells - Drug resistance 	<ul style="list-style-type: none"> - Human MNNG-HOS, U2OS, MG-63 and OSC228 cell lines - Primary cultures of human cancer cells 	27
CD117, Stro-1	<ul style="list-style-type: none"> - Expression of stemness markers (CD133, CXCR4, Nanog, Otc4) - <i>In vivo</i> properties of tumor-initiating cells - Drug resistance (ABCG2): resistance to methotrexate, cis-platin 	<ul style="list-style-type: none"> - Mouse K7M2 cell line - Mouse 318-1, P932 and K7M2 cell lines / Human KHOS and MNNG/HOS cell lines - Human U2OS cell line - Human MG63, MNN/HOS, 143B cell lines and patient-derived cells 	28 29 30 31
CD133	<ul style="list-style-type: none"> - Sphere formation - Expression of stemness markers (Sox2, Oct3/4, Nanog) - Expression of ABCG2, MDR1 - Expression of ABCB1, ABCC2, and the metastasis-associated genes β4-integrin, ezrin, MMP-13, and CXCR4 - Concomitant CD133/CXCR4 expression significantly associated with lung metastasis - Expression of CD133, ALDH1 positively associated with lymph node metastasis, distant metastasis 	<ul style="list-style-type: none"> - Human SaOS2, MG63 and U2OS cell lines - Primary cultures of human cancer cells and human MG63 cell line - FFPE samples and MG63 cell line - SaOS2 cell line - FPPE samples and human SaOS2, U2OS, MG63, HOS, MNNG/HOS, HuO9, 143B cell lines - FFPE samples 	32 33 34 35,36 37 38, 39
CD271	<ul style="list-style-type: none"> - Sphere formation - Ability for self-renewal - Resistance to DDP therapy - Overexpression of Nanog, Oct3/4, STAT3, DNA-PKcs, Bcl-2 and ABCG2 - <i>In vivo</i> tumorigenicity 	<ul style="list-style-type: none"> - FFPE samples and human U2OS, MNNG/HOS, SaOS2 cell lines 	40
ALDH1	<ul style="list-style-type: none"> - Sphere formation - Ability for self-renewal - Expression of stemness markers 	<ul style="list-style-type: none"> - FPPE samples - Human MG63 cell line 	39 41

	(CD133, CXCR4, Nanog, Oct4, Sox2, KLF4) - Drug resistance - <i>In vivo</i> tumorigenicity	- Huma HuO9, OS99-1, MG63, SaOs2 cell lines - Human HOS, MG63, MHM, MNNG/HOS, OHS, U2OS cell lines	42 43
hTERT enrichment	- Expression of CD117, Stro-1 - Spheroid formation	Primary osteosarcoma cell lines (OS1-4) - MG63, MNNG/HOS, 143B cell lines	31
Metabolic properties	- Specific metabolic feature of osteosarcoma stem like cells: amino acid, fatty acid, energy, and nucleic acid. - Involvement of the Rap1 and Ras signaling pathways in methotrexate resistance - High aerobic glycolysis and oxidative phosphorylation: association to LINB28 expression - Downregulation of the citrate cycle and elevation of oxidized glutathione levels. Upregulation of most of the amino acid metabolisms - Uncoupling Warburg and stemness in CD133 ⁺ cells under hypoxia	- Human 143B and MG63 cell lines - Human OS13 cell line - Human HOS cell line - Human SaoS2 cell line	44 45 46 47
N-methyltransferase	- Sphere formation - Expression of CD133, CD44, Oct4, Sox2, Nanog, Nestin, ABCG2, and BMI-1	- Human MG-63 cell line	48
m ⁶ A methylome	- Multidrug resistance - Sphere formation - Overexpression of CD117, stro-1, CD113, stemness markers (<i>SOX2</i> , <i>POU5F1</i> , <i>NANOG</i> and <i>KLF4</i>) - Upregulation of <i>METTL3</i> and <i>ALKBH5</i> of and downregulation of <i>METTL14</i> and <i>FTO</i>	- Human MG63 cell line	49

86


87 Asymmetric cell division has been described in stable cancer cell lines, leading to the development of
88 proliferating and quiescent cells that were functionally related to sensitive and drug resistant cells
89 respectively^[15]. The identification of CSCs in osteosarcoma has been extensively described in the
90 literature (Table 1). CSCs express CD24^[27], CD177^[28-31], Stro-1^[28-31], CD133^[32-39], ALDH1^[39,41-43] and

91 show specific metabolic properties^[44-47]. Telomerase (hTert) controls the lengthening of chromosome
 92 telomeres by catalyzing the addition of repetitive DNA sequence to their end. CD271, and Stro-1 were
 93 enriched in hTert and showed metabolic specificities such an uncoupling Warburg under hypoxia^[31, 47]. In
 94 addition, as expected, these cells which expressed stemness markers (e.g. *Nanog*, *OCT4*, *Sox2*), were
 95 able to form spheroids *in vitro*, and exhibited the properties of tumor-initiating cells in preclinical mouse
 96 models^[47]. Among the other metabolic particularities, CSCs exhibit high aerobic glycolysis and oxidative
 97 phosphorylation^[45], a downregulation of the citrate cycle and an increased oxidative glutathione levels^[46]
 98 and show more generally an upregulated of most of the amino acid metabolism^[44,46]. A drug resistant
 99 profile have been associated with the stemness properties of CSCs which can be modulated by epigenetic
 100 mechanisms such as DNA and mRNA methylation^[48,49] and with an increase in ALDH activity and ABC
 101 transporter expression^[50,51]. Interestingly, anti-cancer therapies based on cytotoxic agents result in
 102 enrichment of CSCs in cancer cells, highlighting the potentially harmful link between CSCs and the
 103 establishment of drug resistance^[52-54]. CSCs may be a specific subset of tumor cells with high potential for
 104 tumor-initiation and self-renewal as has been recently observed in all primary cultures from cases of
 105 patient-derived Ewing sarcoma^[55].

106

107 MOLECULAR REGULATION OF CANCER STEM-LIKE CELLS IN 108 OSTEOSARCOMA

109 Osteosarcoma growth and the distant dissemination of cancer cells are controlled by a permanent dialog
 110 between cancer cells and their microenvironment^[2,56]. These soluble and membranous mediators trigger
 111 specific intracellular molecular cascades that lead to control of cellular processes, including cell death,
 112 epithelial-mesenchymal transition, or spreading, but also proliferation and quiescence. In this context, the
 113 behavior of CSCs is controlled by the tumor microenvironment. In recent decades, key signaling
 114 pathways regulating CSCs have been identified and become the source of therapeutic development
 115 (Figure 1).



116

117 **Figure 1: Main signaling pathways and mechanisms regulating the maintenance of cancer**
 118 **stem-like cells in osteosarcoma. LPR: Lipoprotein Receptor-related Protein FZD: Frizzled receptor;**
 119 **PRL: PRLactin receptor**

120

121 The **Wnt/β-catenin** pathway contributes to the regulation of numerous cellular processes (e.g.
 122 proliferation, differentiation, polarization) and is thus strongly associated with embryonic development.
 123 Wnt glycoprotein family is composed by 19 secreted members that interact with cell membranes after

124 binding to on of the 10 Frizzled (FZD) receptors identified which are G protein-coupled receptors or to a
125 co-receptor such as LRP-5 or -6 or tyrosine kinase receptor chains including retinoic acid-related orphan
126 receptor (ROR) and RyK. In absence of Wnt ligand, β -catenin is degraded by the proteasome after
127 sequestration associated GSK-3 β and the Wnt/ β -catenin pathway is considered as inactive. The
128 Wnt/ β -catenin pathway is activated by the binding of one Wnt ligand to its receptor/co-receptor complex
129 that leads to a series of phosphorylation cascade and recruitment of the receptor chains and then to the
130 inactivation of the β -catenin degradation process. Consequently, β -catenin accumulates to the cytoplasm
131 and is translocated into the nucleus before to interact with transcription factors members of the TCF/LEF
132 family and to activate target genes (Figure 1). Any disturbances (e.g. mutations, activation) in this
133 molecular pathway lead to pathological situations^[57]. Recently, Deng *et al.* studied the involvement of
134 Indian Hedgehog (IHH) signaling in cartilage and bone tumors by deleting *Ptch1* encoding an inhibitor of
135 IHH receptor^[58]. These authors demonstrated that deleting *Ptch1* in mice was associated with an increase
136 in Wnt member expression and the development of skeletal diseases, including osteosarcoma. Interestingly,
137 inhibiting the Wnt/ β -catenin pathway abolished the development of osteosarcoma, highlighting the key
138 role played by this molecular pathway in the pathogenesis of bone sarcomas^[58]. The Wnt/ β -catenin
139 pathway may be the link between tumor development, drug resistance and CSCs in osteosarcoma.
140 Whether or not the Wnt/ β -catenin cascade was related to chemoresistance, it appeared to be a driver of
141 cancer by acting directly on tumor cells, but also by modulating the immune microenvironment^[59]. This
142 cancer driver is persistently activated in the CSCs of osteosarcoma, and the stemness properties induced by
143 chemotherapies are related to activation of the Wnt/ β -catenin cascade^[60,61]. In this context, most molecular
144 machineries that modulate the expression level of Wnt/ β -catenin may affect cancer cell behavior. Thus,
145 epigenetic regulation of Wnt/ β -catenin using the LncRNA DLX6-AS1/miR-129-5p/DLK1 axis or histone
146 methyltransferase SETD2 results in increased stemness properties for osteosarcoma cells, tumor growth,
147 and drug resistance^[62,63]. The key contribution of Wnt/ β -catenin in the maintenance of CSCs may lead to
148 the development of new targeted therapies in osteosarcoma as described below.

149 **IL-6/STAT3** signaling has also been identified as a crucial regulator of bone remodeling and primary bone
150 tumors^[64]. IL-6 family of cytokines composed by 10 members including e.g. IL-11, OSM and LIF induces
151 redundant and pleiotropic activities such as embryogenesis, differentiation or inflammation. Most of the
152 members of this family share the transducing receptor β -subunit gp130 as part of a multimeric receptor
153 complex that includes a specific receptor α -subunit (e.g. IL-6R). The oligomerization of receptor
154 subunits induced by each ligand results in various transduction of signaling pathways dominated by
155 JAK/STAT3 activation and others such as MAPKs, p38 and JNK (Figure 1). In addition to its functions
156 on the tumor microenvironment (e.g. bone and immune cells), the IL-6 signaling pathway controls the
157 maintenance of CSCs in osteosarcoma^[65]. IL-6 released by activated mesenchymal stem cells (MSCs) in
158 the tumor microenvironment promoted osteosarcoma stemness and the spreading properties of cancer
159 cells^[65]. In addition, MSCs supported drug resistance through STAT-3 signaling in cancer cells activated by
160 IL-6^[66]. MSCs and osteosarcoma cells then established a reciprocal dialog initiated by TGF- β containing
161 extracellular vesicles secreted by cancer cells that induced the production of IL-6 by MCSs, which in turn
162 supported stemness, drug resistance, and tumor progression^[67]. The use of active drugs confirmed the
163 contribution of the IL-6/STAT3 axis in osteosarcoma stemness^[68,69].

164 The **TGF β /Smad** axis regulates the self-renewal of osteosarcoma cells. TGF- β $\square\square\square\square\square\square$ belong to a
165 large family of at least 30 secreted proteins sharing structural similarities. TGF- β growth factors are
166 secreted as latent precursors which can bind to specific receptor chains after activation in mature form.
167 TGF- β induces the assembly of type I and type II TGF β -receptors leading to the formation of

168 heteromeric receptors and the initiation of the signal transduction. TGF- β type I receptor shows intrinsic
169 tyrosine kinase activity, phosphorylates the type II chain and initiates the downstream signaling which
170 include Smads phosphorylation. Phospho-Smads complexes are translocated into the nucleus where they
171 cooperate with YAP/TAZ transcription regulators and modulates the transcription of target genes (Figure
172 1). Zhang *et al.* studied the functional impact of TGF- β 1 on osteosarcoma stemness in a hypoxic
173 environment^[70]. They demonstrated the crucial role played by TGF- β 1 on the proliferative state of cancer
174 cells which acquired the stem cell phenotype for self-renewal, drug resistance, neoangiogenesis, and
175 tumorigenicity, and on the contrary, blocking the TGF- β 1 signaling pathway reduced the dedifferentiation
176 program of osteosarcoma cells. Similarly, by using gamabufotalin, a bufadienolide extracted from toad
177 venom, it has recently been demonstrated that blockading the TGF- β /periostin/PI3K/AKT axis resulted in
178 suppression of CSCs in osteosarcoma.^[71] CSCs associated with TGF- β activity were also linked to drug
179 resistance, as shown for EGFR inhibitors highlighting once again the role played by CSCs in the drug
180 resistance process.^[72]

181 Recently, a series of **transcription factors** were identified as regulators of cancer stemness in
182 osteosarcoma. The transcription factor Sox determining the region Y-box 2 (Sox2) plays a key role in
183 developing and controlling the embryonic stem cell state and was identified as a biomarker for CSCs in
184 osteosarcoma (Table 1). In addition, the proliferation of osteosarcoma cells and tumor development
185 requires Sox2^[73]. These authors compared tumor growth in Cre-bearing mice with identical Rb and p53
186 genotypes in a background of Sox2 deficient- or wild-type mice. Tumor development was significantly
187 slowed down in the Sox2 deficient mice compared to the other groups, and the survival rate was also higher
188 in the Sox2 knockout mice. Sox2 appeared essential for the survival and proliferation of all osteosarcoma
189 cells, including CSCs. The Hippo pathway, which is under the transcriptional control of Sox2, was directly
190 related to the same activities, and deactivating Sox2 effectors (e.g. YAP) resulted similarly in a reduction in
191 tumor growth^[73]. Chen *et al.* demonstrated that musculoaponeurotic fibrosarcoma oncogene homolog B
192 (MAFB) is highly expressed in osteosarcoma and more specifically in CSCs and this transcription factor,
193 like Sox2, is required for the proliferation and tumorigenicity of osteosarcoma cells^[74]. Interestingly, they
194 observed that maintaining the self-renewal potential of CSCs was under the transcriptional control of
195 Sox-9, a stem cell regulator^[74]. More recently, STAT-5 associated signaling was identified as a key
196 regulator^[75]. The knockdown of STAT-5 (A and B isoforms) using an siRNA approach reduced
197 pimezide-induced tumor growth in mice in addition to suppressing *in vitro* sphere formation. Inhibiting
198 STAT-5 signaling thus impaired osteosarcoma self-renewal and development^[75]. JAK/STAT-5 activation
199 belongs to the downstream signaling associated to various cytokine/hormone induced signaling pathways
200 including prolactin, IL-2, IL-3, etc. Oct4 promoted osteosarcoma development by supporting the
201 maintenance of CSCs through the increase in AK055347, a long-noncoding (lnc) RNA. Oct4 knockdown
202 with siRNA induced a significant decrease in cell proliferation, invasion and apoptosis^[76]. TBL1XR1 is a
203 transcriptional co-factor which is overexpressed in osteosarcoma patients^[77]. Its overexpression in MG63
204 and U2-OS cell lines induced a CSC phenotype in contrast to its repression. TBL1XR1 thus provides
205 osteosarcoma cells with tumorigenic properties and promotes the recurrence of osteosarcoma in a STAT-3
206 signaling dependent manner^[77]. Transcriptional complexes can also modulate osteosarcoma drug
207 resistance. Thus, CtBP1-FOXM1 transcriptional complex increased *MDR1* expression in osteosarcoma
208 CSCs, which is associated with drug resistance^[78]. Interestingly, small molecules targeting this complex
209 reversed the MDR1-mediated resistance both *in vitro* and in murine preclinical models.

210 Regulating osteosarcoma growth through the oct4-lncRNA axis highlights the epigenetic regulation of
211 osteosarcoma CSCs^[79]. This observation is supported by the rich literature emerging in the last 10 years^[76]

(Table1). In this context, chromodomain helicase DNA binding protein 1-like (CHD1L) significantly reduced osteosarcoma proliferation and drug resistance through its binding to DNA. It also controls chromosomal integrity maintenance, DNA repair, and transcriptional regulation^[79]. Ubiquitin-specific peptidase 39 (USP39) is a crucial factor for assembling mature spliceosome complex and its knockdown leads to the inhibition of osteosarcoma cell proliferation combined with an increase in apoptosis^[80]. Human antigen R (HuR) is involved in stabilizing mRNA, and its repression in osteosarcoma cells reduced their stemness properties and increased the drug response^[81]. These activities were related to YAP activation. Several recent publications showed the role played by specific miRNA in controlling stemness in osteosarcoma and the list includes miR29b and its target Spin1^[82], miR34a^[84] and the DNMT1/miR34a/Bcl2 axis^[84,85], TNF- α -miR155 signaling^[87], miR335 and its target POU5^[88], miR429 and its target Sox2^[89], and the TGF β -miR-499a-SHKBP1 89 axis^[90]. Very recently, leukemia inhibitory factor (LIF) was shown to belong to the IL-6 family of cytokines, similarly activating STAT-3, and was recently revealed as a super-enhancer-controlled regulator of CSC properties, confirming the role of STAT-3 transcription factor in the functional regulation of CSCs in osteosarcoma^[91]. TSSC3 tumor-suppressing STF cDNA 3 (TSSC3), the first apoptosis-related gene reported to be imprinted, repressed the self-renewal of osteosarcoma CSCs^[92]. Finally, lncRNAs also play a part in the biological regulation of CSCs in osteosarcoma^[76,93].

Autophagy^[94,95], **stress response**^[96,98] as well as **numerous enzymatic pathways**^[99-104] complete the landscape of osteosarcoma CSC-regulation mode. Autophagy was shown as a critical biological process for maintaining CSCs in OS^[94] and defective autophagy was directly associated with the decrease in CSCs^[95]. Similarly, the knockdown of stress-induced phosphoprotein 1 (STIP1) resulted in the inhibition of CSC invasiveness and migration^[96]. STIP-1 is a co-chaperone that binds to HSP70 and 90, and consequently inhibits Hsp90 by 17-AAG reduced stem cell-like properties and decreased drug resistance in OS^[97].

236 **THERAPEUTIC TARGETING OF CANCER STEM-LIKE CELLS IN** 237 **OSTEOSARCOMA**

238 The recent evidence of CSCs in osteosarcoma, and better understanding of the molecular pathways
239 required for their maintenance, led to the identification of new therapeutic targets summarized in Table 2.
240 Repressing the signaling pathways related to the maintenance of CSCs (see Table 1) resulted in the
241 slowdown of tumor growth and inhibition of the metastatic process^[105-116]. As previously mentioned,
242 Wnt/ β -catenin appeared crucial for the maintenance of CSCs and its attenuation by using tankyrase
243 inhibitor or tegavivint was associated with a decrease in both CSC numbers and tumor progression^[105,106].
244 GSK3 appeared highly expressed in osteosarcoma and targeting Akt/GSK3/ β -catenin or
245 Akt/GSK3-/Notch-1 respectively with \square dioscein or tideglusib repressed CSC and tumor growth^[107,108].
246 Gamabufotalin induced similar activities by targeting TGF- β /periostin/PI3K/Akt signaling^[109]. Similar
247 results were obtained by targeting BMP2R^[110]. Drugs targeting transcription factors (e.g. STAT-3, STAT5)
248 controlling the development of CSCs may be also used to improve the therapeutic approaches to
249 osteosarcoma^[75,111,112]. Activation of hormone signaling can reduce stemness in osteosarcoma, as shown by
250 the activation of estrogen receptor alpha by decitabine^[113]. Most of the cytokine induced signaling
251 pathways results in the translocation of transcription factors which modulate the transcription of target
252 genes. Targeting of such transcription factors (e.g. KLF4, Sox9) may be used for reducing CSCs in
253 osteosarcoma^[114-116]. Similarly, ROCK inhibition by fasudil suppressed *in vitro* cell proliferation and
254 reduced their tumorigenicity *in vivo*^[100]. Cell metabolism is significantly modulated in CSCs (e.g.

255 autophagy, cell cycle) and these specificities can be used for targeting CSCs in osteosarcoma. For instance,
 256 thioridazin and metformin target autophagy and metformin and wogomin modulated ROS-mediated
 257 apoptosis in CSCs and resensitize CSCs to cell death^[114-116]. Similarly, regulation of cell cycle by
 258 DMAMCL or inhibition of γ -secretase by DAPT will affect the behavior of CSCs and their function in
 259 tumor growth^[122-123].

260

261 **Table 2: Potential therapeutic approach to CSCs in osteosarcoma**

Drug	Molecular pathway involved or therapeutic approaches	Reference
Wnt/β-catenin targeting		
Tankyrase inhibitor (IWR-1)	Attenuation of Wnt/ β -catenin signaling	105
Tegavivint	β -catenin/transducin β -like protein 1 (TBL1) inhibition	106
Dioscein	Akt/GSK3/ β -catenin	107
Tideglusib	GSK-3 β /NOTCH1	108
TGF-β/BMP2 targeting		
Gamabufotalin	TGF- β /periostin/PI3K/AKT	109
BMP2	BMP2 receptor signaling	110
Other receptor signaling targeting (STAT-3, STAT-5, ER-α, TRAF-2, etc) and transcription factors		
Bruceine D	STAT-3 inhibition	111
Pimozide	STAT-5 signaling	75,112
Decitabine	Activation of estrogen receptor alpha (ER- α)	113
NCB-0846	TRAF2- and NCK-interacting protein kinase	114
Melatonin	Suppression of SOX9 mediated signaling	115
Statins	KLF4	116
Targeting of kinase activities		
Fasudil	Rho-associated coiled-coil containing kinase (ROCK) inhibition	100
Autophagy and metabolic targeting		
Thioridazine	Autophagy	94
Metformin	- Inhibition of mitochondrial functions (decrease in oxygen assumption, decreased mitochondrial membrane potential, decreased ATP production)	117
	- Pyruvate kinase isoenzyme M2 (PKM2)	118
	- ROS-mediated apoptosis and autophagy	119
	- Activation and phosphorylation of the energetic sensor AMPK	120
Wogonin	ROS regulation	121
DMAMCL	Cell cycle	122
DAPT	γ -secretase inhibition	123
Combinations with chemotherapy and sensitization to chemotherapy		
Ascorbate	Sensitization to cisplatin	124
Ouabain	Sensitization to cisplatin: Na ⁺ /K ⁺ ATPase inhibition	125
Tangeretin-assisted platinum	Combination with doxorubicin	126

nanoparticles Senolytic drug (Fisetin)	Combination with etoposide	127
Immunotherapy		
Immunotherapy based on cytokine induced killer cells	CSCs spared after chemotherapy or other targeted therapies	129
Modulation of epigenetic events		
Epigenetic targeting	- USP39 silencing	80
	- HuR knockdown	81
	- Disruption of the DNMT1/miR34a/Bcl-2 axis by Isovitexin	85
	- LncRNA HOXD-AS1 knockdown	
	- RAB39A silencing	92
	- Targeting of LncRNA SOX2OT variant 7 by EGCG (polyphenol isolated from green tea)	99
		130
Photo Therapy		
Graphene Oxide Nanoparticle loaded Ginsenoside Rg3	Photodynamic therapy	131
CD271 antibody-functionalized HGNs	Photothermal therapy	132
Drug delivery systems		
Salinomycin-loaded PLA nanoparticles	Delivery of solinomycin	133
Lipid-polymer nanoparticles with CD133 aptamers	Delivery of all-trans retinoic acid	134
Lipid-polymer nanoparticles with EGFR and CD133 aptamers	Delivery of salinomycin	135

262

263 Drugs/effective agents can be used as sensitization agents to chemotherapy^[124,125] or in combination with
 264 chemotherapeutic drugs^[126,127]. Numerous cytokines are involved in the control of local immunity of
 265 cancer cells^[128] and immunotherapies have been proposed for targeting CTCs^[129]. Specific silencing of the
 266 epigenetic partners of CSCs can induce similar regression in tumor growth and metastatic development by
 267 altering CSC maintenance^[80,81,95,92,99,129]. Nanoparticles can be used for developing phototherapies and
 268 drug delivery systems. In this context, nanoparticles have been functionalized and adapted for
 269 phototherapy with a specific aim to improve the targeting of CSCs using^[131,132]. Finally, drug delivery
 270 systems has also been proposed^[133-135]. All these therapeutic approaches, the question of the general
 271 toxicity in healthy tissue stem cells and the specificity of the targeting remains unanswered.

272

273 CONCLUSION

274 Long considered as controversial, today CSCs are a realistic therapeutic target in osteosarcoma^[1,2].
 275 Osteosarcoma remains a highly heterogeneous oncological entity in perpetual evolution due to a strong
 276 clonal dynamic^[136] leading to very efficient adaptation to drugs and the establishment of drug resistance^[15].
 277 The dynamic properties of tumor evolution have led to numerous questions about CSCs and their
 278 functional impact: i) Can we detect CSCs in the bloodstream and can we use circulating tumor cells to
 279 follow the minimal residual disease and identify personalized therapeutic options^[137]? ii) Are CSCs
 280 capable of migrating to distant organs to establish metastatic foci? iii) Is the dynamic evolution of

281 osteosarcoma similar in the primary site and in the metastatic foci? iv) What is the functional regulation
282 of CSCs and are they under the control of proliferating osteosarcoma cells? v) Are CSCs regulated by the
283 tumor microenvironment, and by which molecular pathways? vi) Can we use immune therapies in
284 combination with other drugs (e.g. chemotherapy) to target CSCs and improve overall survival in
285 osteosarcoma? vii) How can we specifically control CSC metabolism and consequently can we set up
286 specific therapeutic options to control CSC wake-up? viii) As osteosarcoma is a form of cancer that
287 originates in the mesenchyme, can we use the fibrogenic reprogramming of CSCs as a therapeutic
288 option^[138]? Even whether sarcomas are considered as an immune desert explaining the current poor
289 clinical efficacy of immune therapies^[1,128]. Macrophage and stromal cells contribute to the establishment
290 of drug resistance and could be envisaged as therapeutic target in osteosarcoma^[139]. For instance, M2
291 macrophage may be associated with tumor angiogenesis. Tumor cells released high amount of protons that
292 induced local acidosis, favored the release of inflammatory mediators by local stromal cells which in turn
293 facilitated tumor invasiveness and metastasis in osteosarcoma^[140]. Overall, it has been demonstrated that
294 stromal cells significantly contributed to increase the stemness properties of osteosarcoma cells by
295 inducing metabolic reprogramming of cancer cells^[141,142]. Consequently, stromal cells constitute an
296 interesting reservoir of stemness targeting to reduce osteosarcoma progression as it as been shown
297 recently^[1413]. A better understanding of the role of stromal cells in the control of stemness would help to
298 identify new mediators associated with stemness, drug resistance and tumor progression. Overall, CSCs
299 are promising targets in osteosarcoma as demonstrated by the most recent data described in this review,
300 paving the way for a new therapeutic era focused on better-controlled residual disease in osteosarcoma
301 through targeting CSCs.

302

303 **DECLARATIONS**

304 **Authors' contributions**

305 DH supervised the work proposed and took the lead in writing the manuscript. CJ, JMG, DC, MFH and
306 contributed to the preparation of the manuscript. All authors approved the version submitted.

307

308 **Financial support and sponsorship**

309 This work was supported by an internal ICO grant 2018 (ref# "DorSarc-2018-ICO-DH").

310

311 **Conflicts of interest**

312 Camille Jubelin is an employee of Atlantic Bone Screen and prepared her PhD at the Université de
313 Nantes (FR). Dominique Heymann is a member of the Editorial board of Cancer Drug Resistance.

314

315 **Copyright**

316 © The Author(s) 2021.

317 **REFERENCES**

- 318 [1] Grünewald TGP, Alonso M, Avnet S, et al. Sarcoma treatment in the era of molecular medicine. *EMBO*
319 *Mol Med* 2020;12:e11131. [PMID: 33047515 DOI: 10.15252/emmm.201911131]
320 [2] Brown HK, Schiavone K, Gouin F, Heymann MF, D Heymann. Biology of bone sarcomas and new
321 therapeutic developments. *Calcif Tissue Int* 2018;102(2):174-95. [PMID: 29238848 DOI:
322 10.1007/s00223-017-0372-2]

- 323 [3] Baumhoer D, Böhling TO, Cates JMM, et al. Osteosarcoma. In: WHO Classification of Tumours
324 Editorial board. Soft tissue and bone tumours. Lyon (France): International Agency for Research on
325 Cancer; 2020. pp 403-9.
- 326 [4] Flanagan AM, Bridge JA, O'Donnell PG. Secondary osteosarcoma. In: WHO Classification of
327 Tumours Editorial board. Soft tissue and bone tumours. Lyon (France): International Agency for
328 Research on Cancer; 2020. pp 419-21.
- 329 [5] Gill J, Gorlick R. Advancing therapy for osteosarcoma. *Nat Rev Clin Oncol* 2021;18(10):609-24.
330 [PMID: 34131316 DOI: 10.1038/s41571-021-00519-8]
- 331 [6] Strauss SJ, Whelan SJ. Current questions in bone sarcomas. *Curr Opin Oncol* 2018; 30(4):252-59.
332 [PMID: 29782347 DOI:10.1097/CCO.0000000000000456]
- 333 [7] The ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice
334 Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2012;23: vii100-vii109.
335 [doi:10.1093/annonc/mds254]
- 336 [8] Kovac M, Blattmann C, Ribi S, et al. Exome sequencing of osteosarcoma reveals mutation signatures
337 reminiscent of BRCA deficiency. *Nat Commun* 2015 Dec 3;6:8940. [PMID: 26632267 DOI:
338 10.1038/ncomms9940]
- 339 [9] Behjati S, Tarpey PS, Haase K, et al. Recurrent mutation of IGF signalling genes and distinct patterns
340 of genomic rearrangement in osteosarcoma. *Nat Commun* 2017;8:15936. [PMID: 28643781 DOI:
341 10.1038/ncomms15936]
- 342 [10] Wu SP, Cooper BT, Bu F, et al. DNA Methylation-Based Classifier for Accurate Molecular Diagnosis
343 of Bone Sarcomas. *JCO Precis Oncol* 2017;2017:PO.17.00031. [PMID: 29354796 DOI:
344 10.1200/PO.17.00031]
- 345 [11] Morrow JJ, Bayles I, Funnell APW, et al. Positively selected enhancer elements endow osteosarcoma
346 cells with metastatic competence. *Nat Med* 2018;24(2):176-185. [PMID:29334376 DOI:
347 10.1038/nm.4475]
- 348 [12] Asano N, Takeshima H, Yamashita S, et al. Epigenetic reprogramming underlies efficacy of DNA
349 demethylation therapy in osteosarcomas. *Sci Rep* 2019;9(1):20360. [PMID: 31889115 DOI:
350 10.1038/s41598-019-56883].
- 351 [13] Brown HK, Tellez-Gabriel M, Cartron PF, Vallette FM, Heymann MF, Heymann D. Characterization
352 of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality? *Drug Discov*
353 *Today* 2019;24(3):763-72. [PMID: 30496853 DOI: 10.1016/j.drudis.2018.11.017]
- 354 [14] Tellez Gabriel M, Heymann MF, Heymann D. Circulating tumor cells as a tool for assessing tumor
355 heterogeneity. *Theranostic* 2019;9(16):4580-94. [PMID: 31367241 DOI: 10.7150/thno.34337].
- 356 [15] Vallette FM, Olivier C, Lézot F et al. Dormant, quiescent, tolerant and persister cells: four synonyms
357 for the same target in cancer. *Biochem Pharmacol* 2019;162:169-76. [PMID: 30414937 DOI:
358 10.1016/j.bcp.2018.11.004].
- 359 [16] Nassar D, Blanpain C. Cancer stem cells: basic concepts and therapeutic implications. *Annu Rev*
360 *Pathol* 2016;11:47-76. [PMID: 27193450 DOI: 10.1146/annurev-pathol-012615-044438]
- 361 [17] Walcher L, Kistenmacher AK, Suo H, et al. Cancer stem cells-orgins and biomarkers: perspectives for
362 targeted personalized therapies. *Front Immunol* 2020;11:1280. [PMID: 32849491 DOI:
363 10.3389/fimmu.2020.01280]
- 364 [18] Clarke MF. Clinical and therapeutic implications of cancer stem cells. *N Engl J Med*
365 2019;380(23):2237-245. [PMID: 31167052 DOI: 10.1056/NEJMra1804280]
- 366 [19] Halldorsson A, Brooks S, Montgomery S, Graham S. Lung metastasis 21 years after initial diagnosis

- 367 of osteosarcoma: a case report. *J Med Case Rep* 2009;3:9298. [PMID: 20062787 DOI:
368 10.1186/1752-1947-3-9298]
- 369 [20] Perrot P, Rousseau J, Bouffaut AL, et al. Safety control between autologous fat graft, mesenchymal
370 stem cells and osteosarcoma recurrence. *PLoS One* 2010;5(6):e10999. [PMID: 20544017 DOI:
371 10.1371/journal.pone.0010999]
- 372 [21] Pantel K, Alix-Panabières C. Tumour microenvironment: informing on minimal residual disease in
373 solid tumours. *Nat Rev Clin Oncol* 2017;14(6):325-26. [PMID: 28397823 DOI:
374 10.1038/nrclinonc.2017.53]
- 375 [22] Ferrari S, Bacci G, Picci P, et al. Long-term follow-up and post-relapse survival in patients with
376 non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. *Ann Oncol*.
377 1997;8(8):765-71. [PMID: 9332684 doi: 10.1023/a:1008221713505]
- 378 [23] Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the
379 extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma
380 study group protocols. *J Clin Oncol* 2002;20(3):776-90. [PMID: 11821461 DOI:
381 10.1200/JCO.2002.20.3.776]
- 382 [24] Smeland S, Bielack SS, Whelan J, et al. Survival and prognosis with osteosarcoma: outcomes in more
383 than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. *Eur J*
384 *Cancer* 2019;109:36-50. [PMID: 30685685 DOI: 10.1016/j.ejca.2018.11.027]
- 385 [25] Pennati A, Riggion E, Marano G, Biganzoli E. Autologous fat grafting after sarcoma surgery:
386 Evaluation of oncological safety. *J Plast Reconstr Aesthet Surg* 2018;71(12):1723-29. [PMID:
387 30224167 DOI: 10.1016/j.bjps.2018.07.028].
- 388 [26] Le Nail LR, Brennan M, Rosset P, et al. Comparison of tumor- and bone marrow-derived
389 mesenchymal stromal/stem cells from patients with high-grade osteosarcoma. *Int J Mol Sci*
390 2018;19(3):707. [PMID: 29494553 DOI: 10.3390/ijms19030707].
- 391 [27] Zhou Z, Li Y, Kuang M, et al. The CD24⁺ cell subset promotes invasion and metastasis in human
392 osteosarcoma. *EBioMed* 2020;51:102598. [PMID: 31901872 DOI: 10.1016/j.ebiom.2019.102598]
- 393 [28] Shao XJ, Xiang SF, Chen YQ, et al. Inhibition of M2-like macrophages by all-trans retinoic acid
394 prevents cancer initiation and stemness in osteosarcoma cells. *Acta Pharmacol Sin*
395 2019;40(10):1343-350. [PMID: 31296953 DOI: 10.1038/s41401-019-0262-4]
- 396 [29] Adhikari AS, Agarwal N, Wood BM, et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating
397 cells associated with metastasis and drug resistance. *Cancer Res* 2010;70(11):4602-12. [PMID:
398 20460510 DOI: 10.1158/0008-5472]
- 399 [30] Tang QL, Liang Y, Xie XB, et al. Enrichment of osteosarcoma stem cells by chemotherapy. *Chinese*
400 *J Cancer* 2011;30(6):426-32. [PMID 21627865 DOI: 10.5732/cjc.011.10127]
- 401 [31] Yu L, Liu S, Zhang C, et al. Enrichment of human osteosarcoma stem cells based on hTERT
402 transcriptional activity. *Oncotarget* 2013;4(12):2326-38. [PMID: 24334332
403 DOI: 10.18632/oncotarget.1554]
- 404 [32] Tirino V, Desiderio V, d'Aquino R, et al. Detection and characterization of CD133+ cancer stem
405 cells in human solid tumours. *PloS one* 2008;3(10):e3469. [PMID: 18941626 DOI:
406 10.1371/journal.pone.0003469]
- 407 [33] Tirino V, Desiderio V, Paino F, De Rosa A, et al. Human primary bone sarcomas contain CD133+
408 cancer stem cells displaying high tumorigenicity in vivo. *FASEB J* 2011;25(6):2022-30. [PMID:
409 21385990 DOI: 10.1096/fj.10-179036]
- 410 [34] He A, Qi W, Huang Y, Feng T, et al. CD133 expression predicts lung metastasis and poor prognosis

- 411 in osteosarcoma patients: A clinical and experimental study. *Exp Ther Med* 2012;4(3):435-41. [PMID:
412 23181114 DOI: 10.3892/etm.2012.603]
- 413 [35] Li J, Zhong XY, Li ZY, Cai JF, Zou L, Li JM, et al. CD133 expression in osteosarcoma and
414 derivation of CD133(+) cells. *Mol Med Rep* 2013;7(2):577-84. [PMID: 23242469 DOI:
415 10.3892/mmr.2012.1231]
- 416 [36] Ozturk S, Gorgun C, Gokalp S, Vatansever S, Sendemir A. Development and characterization of
417 cancer stem cell-based tumoroids as an osteosarcoma model. *Biotechnol Bioeng*
418 2020;117(8):2527-2539. [PMID: 32391924 DOI: 10.1002/bit.27381]
- 419 [37] Fujiwara T, Katsuda T, Hagiwara K, et al. Clinical relevance and therapeutic significance of
420 microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells. *Stem*
421 *Cells* 2014;32(4):959-73. [PMID 24715690 DOI: 10.1002/stem.1618]
- 422 [38] Mardani A, Gheythanvi E, Mousavie SH, Jabari JM, Shooshtarizadeh T. Clinical Significance of
423 Cancer Stem Cell Markers CD133 and CXCR4 in Osteosarcomas. *Asian Pac J Cancer Prev*
424 2020;21(1):67-73. [PMID: 31983166 DOI: 10.31557/APJCP.2020.21.1.67]
- 425 [39] Bao Z, Cheng Z, Chai D. The expressions of CD133, ALDH1, and vasculogenic mimicry in
426 osteosarcoma and their clinical significance. *Int J Clin Exp Pathol* 2018;11(7):3656-63. [PMID:
427 31949746]
- 428 [40] Tian J, Li X, Si M, Liu T, Li J. CD271+ osteosarcoma cells display stem-like properties. *PLoS One*
429 2014;9(6):e98549. [PMID: 24893164 DOI: 10.1371/journal.pone.0098549]
- 430 [41] Honoki K, Fujii H, Kubo A, et al. Possible involvement of stem-like populations with elevated
431 ALDH1 in sarcomas for chemotherapeutic drug resistance. *Oncol Rep* 2010;24(2):501-5.
432 [PMID:20596639 DOI: 10.3892/or_00000885]
- 433 [42] Wang L, Park P, Zhang H, La Marca F, Lin CY. Prospective identification of tumorigenic
434 osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. *Int J*
435 *Cancer* 2011;128(2):294-303. [PMID:20309879 DOI: 10.1002/ijc.25331]
- 436 [43] Martins-Neves SR, Paiva-Oliveira DI, Wijers-Koster PM, Abrunhosa AJ, Fontes-Ribeiro C, Bovee
437 JV, et al. Chemotherapy induces stemness in osteosarcoma cells through activation of
438 Wnt/beta-catenin signaling. *Cancer Lett* 2016;370(2):286-95. [PMID: 26577806 DOI:
439 10.1016/j.canlet.2015.11.013].
- 440 [44] Wang F, Zhang Z, Li Q, Yu T, Ma C. Untargeted LC-MS/MS analysis reveals metabolomics feature of
441 osteosarcoma stem cell response to methotrexate. *Cancer Cell Int* 2020;20:269. [PMID: 32587477
442 DOI: 10.1186/s12935-020-01356-y].
- 443 [45] Mizushima E, Tsukahara T, Emori M, et al. Osteosarcoma-initiating cells show high aerobic
444 glycolysis and attenuation of oxidative phosphorylation mediated by LIN28B. *Cancer Sci*
445 2020 ;111(1):36-46. [PMID: 31705593 DOI: 10.1111/cas.14229].
- 446 [46] Zhong Z, Mao S, Lin H, Li H, Lin J, Lin JM. Alteration of intracellular metabolome in osteosarcoma
447 stem cells revealed by liquid chromatography-tandem mass spectrometry. *Talanta* 2019;204:6-12.
448 [PMID: 31357340 DOI: 10.1016/j.talanta.2019.05.088].
- 449 [47] Koka P, Mundre RS, Rangarajan R, Chandramohan Y, Subramanian RK, Dhanasekaran A.
450 Uncoupling Warburg effect and stemness in CD133⁺ cancer stem cells from Saos-2 (osteosarcoma)
451 cell line under hypoxia. *Mol Biol Rep* 2018;45(6):1653-1662. [PMID: 30128626 DOI:
452 10.1007/s11033-018-4309-2].
- 453 [48] Pozzi V, Salvolini E, Lucarini G, et al. Cancer stem cell enrichment is associated with enhancement of
454 nicotinamide N-methyltransferase expression. *IUBMB Life* 2020;72(7):1415-1425. [PMID: 32150326

- 455 DOI: 10.1002/iub.2265]
- 456 [49] Wang Y, Zeng L, Liang C, et al. Integrated analysis of transcriptome-wide m⁶A methylome of
457 osteosarcoma stem cells enriched by chemotherapy. *Epigenomics* 2019; 11(15):1693-1715. [PMID:
458 31650864 DOI:10.2217/epi-2019-0262]
- 459 [50] Menéndez ST, Gallego B, Murillo D, Rodríguez A, Rodríguez R. Cancer stem cells as a source of
460 drug resistance in bone sarcomas. *J Clin Med* 2021;10(12):2621. [PMID: 34198693 DOI:
461 10.3390/jcm10122621]
- 462 [51] Belayneh R, Weiss K. The Role of ALDH in the metastatic potential of osteosarcoma cells and
463 potential ALDH targets. *Adv Exp Med Biol* 2020;1258:157-166. [PMID: 32767240 DOI:
464 10.1007/978-3-030-43085-6_10]
- 465 [52] Tsuchida R, Das B, Yeger H, Koren G, Shibuya M, Thorner PS, et al. Cisplatin treatment increases
466 survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1
467 autocrine signaling. *Oncogene* 2008;27(28):3923-34. [PMID: 18332870 DOI: 10.1038/onc.2008.38]
- 468 [53] Sun DX, Liao GL, Liu KG, Jian H. Endosialin-expressing bone sarcoma stem-like cells are highly
469 tumor-initiating and invasive. *Mol Med Rep.* 2015;12(4):5665-70 [PMID: 26300407 DOI:
470 10.3892/mmr.2015.4218]
- 471 [54] Di Fiore R, Santulli A, Ferrante RD, et al. Identification and expansion of human
472 osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment. *J Cell Physiol*
473 2009;219(2):301-13. [PMID 19160414 DOI: 10.1002/jcp.21667]
- 474 [55] Roundhill EA, Chicon-Bosch M, Jeys L, Parry M, Rankin KS, Droop A, Burchill SA. RNA
475 sequencing and functional studies of patient-derived cells reveal that neurexin-1 and regulators of this
476 pathway are associated with poor outcomes in Ewing sarcoma. *Cell Oncol (Dordr)*
477 2021;44(5):1065-1085. [PMID: 34403115 DOI: 10.1007/s13402-021-00619-8]
- 478 [56] Alfranca A, Martinez-Cruzado L, Tornin J, et al. Bone microenvironment signals in osteosarcoma
479 development. *Cell Mol Life Sci* 2015; 72(16):3097-113. [PMID: 25935149 DOI:
480 10.1007/s00018-015-1918-y]
- 481 [57] Danieau G, Morice S, Rédini F, et al. New insights about Wnt/beta-catenin signaling pathway in
482 primary bone tumors and their microenvironment : a promising target to develop therapeutic strategies ?
483 *Int J Mol Sci* 2019;20(15):3751. [PMID: 31370265 DOI: 10.3390/ijms2015375152]
- 484 [58] Deng Q, Li P, Che M, et al. Activation of hedgehog signaling in mesenchymal stem cells induces
485 cartilage and bone tumor formation via Wnt/ β -Catenin. *Elife* 2019;8:e50208. [PMID: 31482846 DOI:
486 10.7554/eLife.50208]
- 487 [59] Parsons MJ, Tammela T, Dow LE. Wnt as a driver and dependency in cancer. *Cancer Discov*
488 2021;11(10):2413-2429. [PMID: 34518209 DOI: 10.1158/2159-8290.CD-21-0190]
- 489 [60] Martins-Neves SR, Corver WE, Paiva-Oliveira DI, et al. Osteosarcoma stem cells have active
490 Wnt/ β -catenin and overexpress SOX2 and KLF4. *J Cell Physiol* 2016;231(4):876-86. [PMID:
491 26332365 DOI: 10.1002/jcp.25179]
- 492 [61] Martins-Neves SR, Paiva-Oliveira DI, Wijers-Koster PM, et al. Chemotherapy induces stemness in
493 osteosarcoma cells through activation of Wnt/ β -catenin signaling. *Cancer Lett* 2016;370(2):286-95.
494 [PMID: 26577806 DOI: 10.1016/j.canlet.2015.11.013]
- 495 [62] Zhang RM, Tang T, Yu HM, et al. LncRNA DLX6-AS1/miR-129-5p/DLK1 axis aggravates stemness
496 of osteosarcoma through Wnt signaling. *Biochem Biophys Res Commun* 2018;507(1-4):260-266.
497 [PMID 30442366 DOI 10.1016/j.bbrc.2018.11.019]
- 498 [63] Jiang C, He C, Wu Z, et al. Histone methyltransferase SETD2 regulates osteosarcoma cell growth and

- 499 chemosensitivity by suppressing Wnt/ β -catenin signaling. *Biochem Biophys Res Commun*
500 2018;502(3):382-388. [PMID 29842882 DOI: 10.1016/j.bbrc.2018.05.176]
- 501 [64] Blanchard F, Duplomb L, Baud'huin M, et al. The dual role of IL-6 type cytokines on bone
502 remodeling and bone tumors. *Cytokine Growth Factor Rev* 2009;20(1):19-28. [PMID: 19038573 DOI:
503 10.1016/j.cytogfr.2008.11.004]
- 504 [65] Cortini M, Massa A, Avnet S, et al. Tumor-activated mesenchymal stromal cells promote
505 osteosarcoma stemness and migratory potential via IL-6 secretion. *PLoS One* 2016;11(11):e0166500.
506 [PMID: 27851822 DOI: 10.1371/journal.pone.0166500]
- 507 [66] Tu B, Zhu J, Liu S, Wang L, Fan Q, Hao Y, Fan C, Tang TT. Mesenchymal stem cells promote
508 osteosarcoma cell survival and drug resistance through activation of STAT3. *Oncotarget*
509 2016;7(30):48296-48308. [PMID: 27340780 DOI: 10.18632/oncotarget.10219]
- 510 [67] Baglio SR, Lagerweij T, Pérez-Lanzón M, et al. Blocking tumor-educated MSC paracrine activity
511 halts osteosarcoma progression. *Clin Cancer Res* 2017;23(14):3721-3733. [PMID: 28053020 DOI:
512 10.1158/1078-0432.CCR-16-2726]
- 513 [68] Zhang C, Ma K, Li W. Cinobufagin suppresses the characteristics of osteosarcoma cancer cells by
514 inhibiting the IL-6-OPN-STAT3 pathway. *Drug Des Devel Ther* 2019;13:4075-4090. [PMID:
515 31824138 DOI: 10.2147/DDDT.S224312]
- 516 [69] Wang S, Hu H, Zhong B, et al. Bruceine D inhibits tumor growth and stem cell-like traits of
517 osteosarcoma through inhibition of STAT3 signaling pathway. *Cancer Med* 2019 ; 8(17):7345-7358.
518 [PMID: 31631559 DOI: 10.1002/cam4.2612]
- 519 [70] Zhang H, Wu H, Zheng J et al. Transforming growth factor β 1 signal is crucial for dedifferentiation of
520 cancer cells to cancer stem cells in osteosarcoma. *Stem Cells* 2013;31(3):433-46. PMID: 23225703
521 DOI: 10.1002/stem.1298.
- 522 [71] Ma K, Zhang C, Li W. Gamabufotalin suppressed osteosarcoma stem cells through the
523 TFG-beta/periostin/PI3K/AKT pathway. *Chem Biol Interact* 2020;331:109275. [PMID: 33010222
524 DOI: 10.1016/j.cbi.2020.109275].
- 525 [72] Wang T, Wang D, Zhang L, Yang P, Wang J, Liu Q, Yan F, Lin F. The TGFbeta-miR-499a-SHKBP1
526 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells. *J Exp Clin*
527 *Cancer Res* 2019;38(1):226. [PMID: 31138318 DOI: 10.1186/s13046-019-1195-y]
- 528 [73] Maurizi G, Verma N, Gadi A, et al. Sox2 is required for tumor development and cancer cell
529 proliferation in osteosarcoma. *Oncogene* 2018;37(33):4626-4632. [PMID 2974593 DOI:
530 10.1038/s41388-018-0292-2]
- 531 [74] Chen Y, Wang T, Huang M, et al. MAFB promotes cancer stemness and tumorigenesis in
532 osteosarcoma through a Sox9-mediated positive feedback loop. *Cancer Res* 2020;80(12):2472-2483.
533 [PMID: 32234710 DOI: 10.1158/0008-5472.CAN-19-1764]
- 534 [75] Subramaniam D, Angulo P, Ponnurangam, et al. Suppressing STAT5 signaling affects osteosarcoma
535 growth and stemness. *Cell Death Dis* 2020;11(2):149. [PMID: 32094348 DOI:
536 10.1038/s41419-020-2335-1]
- 537 [76] Fan H, Liu G, Zhao C, et al. Transcription factor Oct4 promotes osteosarcoma by regulating lncRNA
538 AK055347. *Oncol Lett* 2017;13(1):396-402. [PMID: 28123573 DOI: 10.3892/ol.2016.5400]
- 539 [77] Xi X, Wu Q, Bao Y, et al. Overexpression of TBL1XR1 confers tumorigenic capability and promotes
540 recurrence of osteosarcoma. *Eur J Pharmacol* 2019;844:259-267. [PMID 30529193 DOI:
541 10.1016/j.ejphar.2018.12.013]
- 542 [78] Chen X, Zhang Q, Dang X et al. Targeting the CtBP1-FOXO1 transcriptional complex with small

- 543 molecules to overcome MDR1-mediated chemoresistance in osteosarcoma cancer stem cells. *J Cancer*
544 2021;12(2):482-497. [PMID: 33391445 DOI: 10.7150/jca.50255]
- 545 [79] Fan GT, Ling ZH, He ZW, Wu SJ, Zhou GX. Suppressing CHD1L reduces the proliferation and
546 chemoresistance in osteosarcoma. *Biochem Biophys Res Commun* 2021 May 21;554:214-221. [PMID:
547 33813077 DOI: 10.1016/j.bbrc.2020.12.109]
- 548 [80] Gan Z, Han K, Lin S, et al. Knockdown of ubiquitin-specific peptidase 39 inhibited the growth of
549 osteosarcoma cells and induced apoptosis in vitro. *Biol Res* 2017;50(1):15. [PMID 28403900 DOI:
550 10.1186/s40659-017-0121-z]
- 551 [81] Xu W, Chen C, Xu R, et al. Knockdown of HuR represses osteosarcoma cells migration, invasion and
552 stemness through inhibition of YAP activation and increases susceptibility to chemotherapeutic agents.
553 *Biomed Pharmacother* 2018;102:587-593. [PMID 29597092 DOI: 10.1016/j.biopha.2018.03.098]
- 554 [82] Li S, Bai H, Chen X et al. Soft substrate promotes osteosarcoma cell self-renewal, differentiation, and
555 drug resistance through miR-29b and its target protein Spin 1. *ACS Biomater Sci Eng*
556 2020;6(10):5588-5598. [PMID: 33320589 DOI: 10.1021/acsbiomaterials.0c00816]
- 557 [83] Zou Y, Huang Y, Yang J, et al. miR-34a is downregulated in human osteosarcoma stem-like cells and
558 promotes invasion, tumorigenic ability and self-renewal capacity. *Mol Med Rep*
559 2017 ;15(4):1631-1637. [PMID: 28260055 DOI: 10.3892/mmr.2017.6187]
- 560 [84] Liang X, Xu C, Wang W, et al. The DNMT1/miR-34a axis Is Involved in the stemness of human
561 osteosarcoma cells and derived stem-like cells. *Stem Cells Int* 2019;2019:7028901. [PMID: 31781245
562 DOI: 10.1155/2019/7028901]
- 563 [85] Liang X, Xu C, Cao X, et al. Isovitexin suppresses cancer stemness property and induces apoptosis of
564 osteosarcoma cells by disruption of the DNMT1/miR-34a/Bcl-2 axis. *Cancer Manag Res*
565 2019;11:8923-8936. [PMID: 31686915 DOI : 10.2147/CMAR.S222708]
- 566 [86] Yao J, Lin J, He L, et al. TNF- α /miR-155 axis induces the transformation of osteosarcoma cancer stem
567 cells independent of TP53INP1. *Gene* 2020;726:144224. [PMID: 31669646 DOI:
568 10.1016/j.gene.2019.144224]
- 569 [87] Guo X, Yu L, Zhang Z, et al. miR-335 negatively regulates osteosarcoma stem cell-like properties by
570 targeting POU5F1. *Cancer Cell Int* 2017;17:29. [PMID: 28239298 DOI: 10.1186/s12935-017-0398-6]
- 571 [88] Zhang L, Yang P, Liu Q, et al. KLF8 promotes cancer stem cell-like phenotypes in osteosarcoma
572 through miR-429-SOX2 signaling. *Neoplasia* 2020;67(3):519-527. [PMID: 32122144 DOI:
573 10.4149/neo_2020_190711N624]
- 574 [89] Wang T, Wang D, Zhang L, et al. The TGF β -miR-499a-SHKBP1 pathway induces resistance to
575 EGFR inhibitors in osteosarcoma cancer stem cell-like cells. *J Exp Clin Cancer Res* 2019;38(1):226.
576 [PMID: 31138318 DOI: 10.1186/s13046-019-1195-y]
- 577 [90] Qu Y, Zheng S, Kang M, et al. Knockdown of long non-coding RNA HOXD-AS1 inhibits the
578 progression of osteosarcoma. *Biomed Pharmacother* 2018;98:899-906. [PMID 29571260 DOI:
579 10.1016/j.biopha.2018.01.024]
- 580 [91] Lu B, He Y, He J, et al. Epigenetic profiling identifies LIF as a super-enhancer-controlled regulator of
581 stem cell-like properties in osteosarcoma. *Mol Cancer Res* 2020;18(1):57-67. [PMID: 31615908 DOI:
582 10.1158/1541-7786.MCR-19-0470]
- 583 [92] Qu Y, Zheng S, Kang M, et al. Knockdown of long non-coding RNA HOXD-AS1 inhibits the
584 progression of osteosarcoma. *Biomed Pharmacother* 2018;98:899-906. [PMID: 29571260 DOI:
585 10.1016/j.biopha.2018.01.024]
- 586 [93] Yan GN, Tang XF, Zhang XC, et al. TSSC3 represses self-renewal of osteosarcoma stem cells and

- 587 Nanog expression by inhibiting the Src/Akt pathway. *Oncotarget* 2017;8(49):85628-85641. [PMID
588 29156746 DOI: 10.18632/oncotarget.20429]
- 589 [94] Camuzard O, Trojani MC, Santucci-Darmanin S, Pagnotta S, Breuil V, Carle GF, Pierrefite-Carle V.
590 Autophagy in osteosarcoma cancer stem cells is critical process which can be targeted by the
591 antipsychotic drug thioridazine. *Cancers* (Basel) 2020;12(12):3675. [PMID: 33297525 DOI:
592 10.3390/cancers12123675]
- 593 [95] Zhang D, Zhao Q, Sun H, et al. Defective autophagy leads to the suppression of stem-like features of
594 CD271⁺ osteosarcoma cells. *J Biomed Sci*. 2016;23(1):82. [PMID: 27863492 DOI:
595 10.1186/s12929-016-0297-5].
- 596 [96] Wang JH, Gong C, Guo FJ, et al. Knockdown of STIP1 inhibits the invasion of CD133-positive
597 cancer stem-like cells of the osteosarcoma MG63 cell line via the PI3K/Akt and ERK1/2 pathways. *Int*
598 *J Mol Med* 2020;46(6):2251-2259. [PMID: 33125116 DOI: 10.3892/ijmm.2020.4764]
- 599 [97] Shu X, Liu H, Zhen R, et al. Hsp90 inhibitor 17-AAG inhibits stem cell-like properties and
600 chemoresistance in osteosarcoma cells via the Hedgehog signaling pathway. *Oncol Rep*
601 2020;44(1):313-324. [PMID: 32377704 DOI: 10.3892/or.2020.7597]
- 602 [98] Zhao T, Meng Y, Wnag Y, Wang W. NDRG1 regulates osteosarcoma cells via mediating the
603 mitochondrial function and CSCs differentiation. *J Orthop Surg Res* 2021 ;16(1):364. [PMID:
604 34099022 DOI: 10.1186/s13018-021-02503-5]
- 605 [99] Prominent role of RAB39A-RXRβ axis in cancer development and stemness. *Oncotarget*
606 2018;9(11):9852-9866. [PMID 29515775 DOI: 10.18632/oncotarget.23955]
- 607 [100] Takahashi N, Nobusue H, Shmizu T, et al. ROCK inhibition induces terminal adipocyte
608 differentiation and suppresses tumorigenesis in chemoresistant osteosarcoma cells. *Cancer Res*
609 2019;79(12):3088-3099. [PMID: 30992323 DOI: 10.1158/0008-5472.CAN-18-2693]
- 610 [101] Liu F, Li L, Li Y, et al. Overexpression of SENP1 reduces the stemness capacity of osteosarcoma
611 stem cells and increases their sensitivity to HSVtk/GCV. *Int J Oncol* 2018;53(5):2010-2020. [PMID
612 30226577 DOI: 10.3892/ijo.2018.4537]
- 613 [102] Tang, ML, Bai XJ, Li Y, et al. MMP-1 over-expression promotes malignancy and stem-like
614 properties of human osteosarcoma MG-63 cells in vitro. *Curr Med Sci* 2018;38(5):809-817. [PMID
615 30594980 DOI: 10.1007/s11596-018-1947-5]
- 616 [103] Zhao T, Meng Y, Wang et al. NDRG1 regulates osteosarcoma cells via mediating the mitochondrial
617 function and CSCs differentiation. *J Orthop Surg Res* 2021;16(1):364. [PMID 34099022 DOI:
618 10.1186/s13018-021-02503-5]
- 619 [104] Feng J, Lan R, Cai G, et al. TREX1 suppression imparts cancer-stem-cell-like characteristics to
620 CD133⁻ osteosarcoma cells through the activation of E2F4 signaling. *Int J Clin Exp Pathol*
621 2019;12(4):1134-1153. [PMID: 31933929]
- 622 [105] Martin-Neves SR, Paiva-Oliveira DI, Fontes-Ribeiro C, et al. IWR-1, a tankyrase inhibitor,
623 attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a
624 subcutaneous human osteosarcoma xenograft. *Cancer Lett* 2018;414:1-15. [PMID: 29126913 DOI:
625 10.1016/j.canlet.2017.11.004]
- 626 [106] Nomura M, Rainusso N, Lee YC, et al. Tegavivint and the β-Catenin/ALDH axis. *J Natl Cancer*
627 *Inst* 2019 ;111(11):1216-1227. [PMID: 30793158 DOI: 10.1093/jnci/djz026]
- 628 [107] Liu W, Zhao Z, Wang Y, et al. Dioscin inhibits stem-cell-like properties and tumor growth of
629 osteosarcoma through Akt/GSK3/β-catenin signaling pathway. *Cell Death Dis* 2018;9(3):343. [PMID:
630 29497056 DOI: 10.1038/s41419-018-0363-x]

- 631 [108] Wei D, Zhu X, Li S, et al. Tideglusib suppresses stem-cell-like features and progression of
632 osteosarcoma by inhibiting GSK-3 β /NOTCH1 signaling. *Biochem Biophys Res Commun* 2021,
633 554 :206-213. [PMID: 33813076 DOI: 10.1016/j.bbrc.2020.12.055]
- 634 [109] Ma K, Zhang C, Li W. Gamabufotalin suppressed osteosarcoma stem cells through the
635 TGF- β /periostin/PI3K/AKT pathway *Chem Biol Interact* 2020;331:109275. [PMID: 33010222 DOI:
636 10.1016/j.cbi.2020.109275]
- 637 [110] Xiong Q, Wang X, Wang L, et al. BMP-2 inhibits lung metastasis of osteosarcoma: an early
638 investigation using an orthotopic model. *Onco Targets Ther* 2018 ;11:7543-7553. [PMID: 30464502
639 DOI: 10.2147/OTT.S176724]
- 640 [111] Wang S, Hu H, Zhong B, et al. Bruceine D inhibits tumor growth and stem cell-like traits of
641 osteosarcoma through inhibition of STAT3 signaling pathway. *Cancer Med* 2019;8(17):7345-7358.
642 [PMID: 31631559 DOI: 10.1002/cam4.2612]
- 643 [112] Gonçalves JM, Barcellos S CA, Correa Rivero ER, et al. Inhibition of cancer stem cells promoted by
644 Pimozide. *Clin Exp Pharmacol Physiol* 2019;46(2):116-125. [PMID: 30383889 DOI:
645 10.1111/1440-1681.13049]
- 646 [113] Lillo Osuna MA, Garcia-lopez J, El Ayachi I, et al. Activation of estrogen receptor alpha by
647 decitabine inhibits osteosarcoma growth and metastasis. *Cancer Res* 2019;79(6):1054-1068. [PMID:
648 30593524 DOI: 10.1158/0008-5472.CAN-18-1255]
- 649 [114] Hirozane T, Masuda M, Sugano T, et al. Direct conversion of osteosarcoma to adipocytes by
650 targeting TNIK. *JCI Insight* 2021;6(3):e137245. [PMID: 33400690 DOI: 10.1172/jci.insight.137245.
- 651 [115] Qu H, Xue Y, Lian W, et al. Melatonin inhibits osteosarcoma stem cells by suppressing
652 SOX9-mediated signaling. *Life Sci* 2018;207:253-264 [PMID: 29689273 DOI:
653 10.1016/j.lfs.2018.04.030]
- 654 [116] Li Y, Xian M, Yang B, et al. Inhibition of KLF4 by statins reverses adriamycin-induced metastasis
655 and cancer stemness in osteosarcoma cells. *Stem Cell Rep* 2017;8(6):1617-1629. [PMID: 28552603
656 DOI: 10.1016/j.stemcr.2017.04.025]
- 657 [117] Deguchi T, Hosoya K, Kim S, et al. Metformin preferentially enhances the radio-sensitivity of
658 cancer stem-like cells with highly mitochondrial respiration ability in HMPOS. *Mol Ther Oncolytics*
659 2021;22:143-151. [PMID: 34514095 DOI: 10.1016/j.omto.2021.08.007]
- 660 [118] Shang D, Wu J, Guo L, et al. Metformin increases sensitivity of osteosarcoma stem cells to cisplatin
661 by inhibiting expression of PKM2. *Int J Oncol* 2017;50(5):1848-1856. [PMID: 28393220 DOI:
662 10.3892/ijo.2017.3950]
- 663 [119] Zhao B, Luo J, Wang Y, et al. Metformin suppresses self-renewal ability and tumorigenicity of
664 osteosarcoma stem cells via reactive oxygen species-mediated apoptosis and autophagy. *Oxid Med Cell
665 Longev* 2019;2019:9290728. [PMID: 31827709 DOI: 10.1155/2019/9290728]
- 666 [120] Paiva-Oliveira DI, Martin-Neves SR, Abrunhosa AJ, et al. Therapeutic potential of the metabolic
667 modulator Metformin on osteosarcoma cancer stem-like cells. *Cancer Chemother Pharmacol*
668 2018;81(1):49-63. [PMID: 29086064 DOI: 10.1007/s00280-017-3467-6]
- 669 [121] Koh H, Sun HN, Xing Z, et al. Wogonin influences osteosarcoma stem cell stemness through
670 ROS-dependent signaling. *In Vivo* 2020;34(3):1077-1084. [PMID: 32354895 DOI:
671 10.21873/invivo.11878]
- 672 [122] Ba G, Hua Z, Xu N, et al. Novel agent DMAMCL suppresses osteosarcoma growth and decreases
673 the stemness of osteosarcoma stem cell. *Cell Cycle* 2020;19(12):1530-1544. [PMID: 32401122 DOI :
674 10.1080/15384101.2020.1762041]

- 675 [123] Dai G, Deng S, Guo W, et al. Notch pathway inhibition using DAPT, a γ -secretase inhibitor (GSI),
676 enhances the antitumor effect of cisplatin in resistant osteosarcoma. *Mol Carcinog* 2019;58(1):3-18.
677 [PMID: 29964327 DOI: 10.1002/mc.22873]
- 678 [124] Oka N, Kumuro A, Amano H, et al. Ascorbate sensitizes human osteosarcoma cells to the cytostatic
679 effects of cisplatin. *Pharmacol Res Perspect* 2020;8(4):e00632. [PMID: 32725721 DOI:
680 10.1002/prp2.632]
- 681 [125] Guo W, Wei B, Cheng T, et al. The Na⁺/K⁺ ATPase inhibitor ouabain attenuates stemness and
682 chemoresistance of osteosarcoma cells. *Med Sci Monit* 2019;25:9426-9434. [PMID: 31822650 DOI:
683 10.12659/MSM.919266]
- 684 [126] Gurunathan S, Jeyarai M, Kang MH, et al. Tangeretin-assisted platinum nanoparticles enhance the
685 apoptotic properties of doxorubicin: combination therapy for osteosarcoma treatment. *Nanomaterials*
686 (Basel) 2019;9(8):1089. [PMID: 31362420 DOI: 10.3390/nano9081089]
- 687 [127] Ferreira de Oliveira JMP, Pacheco AR, Coutinho L, et al. Combination of etoposide and fisetin
688 results in anti-cancer efficiency against osteosarcoma cell models. *Arch Toxicol* 2018;92(3):1205-1214.
689 [PMID: 29270805 DOI: 10.1007/s00204-017-2146-z]
- 690 [128] Heymann MF, Schiavone K, Heymann D. Bone sarcomas in the immunotherapy era. *Br J*
691 *Pharmacol.* 2021;178(9):1955-1972. [PMID: 31975481 doi: 10.1111/bph.14999]
- 692 [129] Mesiano G, Grignani G, Fiorini E, et al. Cytokine Induced Killer cells are effective against sarcoma
693 cancer stem cells spared by chemotherapy and target therapy. *Oncoimmunol* 2018;7(11):e1465161.
694 [PMID: 30393581 DOI: 10.1080/2162402X.2018.1465161]
- 695 [130] Wang W, Chen D, Zhu K. SOX2OT variant 7 contributes to the synergistic interaction between
696 EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition. *J Exp Clin*
697 *Cancer Res* 2018;37(1):37. [PMID: 29475441 DOI: 10.1186/s13046-018-0689-3]
- 698 [131] Lu SL, Wang YH, Liu GF, et al. Graphene Oxide Nanoparticle-Loaded Ginsenoside Rg3 improves
699 photodynamic therapy in inhibiting malignant progression and stemness of osteosarcoma. *Front Mol*
700 *Biosci* 2021;8:663089. [PMID: 33968991 DOI: 10.3389/fmolb.2021.663089]
- 701 [132] Tian J, Gu Y, Li Y, et al. CD271 antibody-functionalized HGNs for targeted photothermal therapy of
702 osteosarcoma stem cells. *Nanotechnology* 2020;31(30):305707. [PMID: 32235073 DOI:
703 10.1088/1361-6528/ab8593]
- 704 [133] Mineo P, Foti C, Vento F, et al. Salinomycin-loaded PLA nanoparticles: drug quantification by GPC
705 and wave voltammetry and biological studies on osteosarcoma cancer stem cells. *Anal Bioanal Chem*
706 2020;412(19):4681-4690. [PMID: 32451642 DOI: 10.1007/s00216-020-02721-6]
- 707 [134] Gui K, Zhang X, Chen F, et al. Lipid-polymer nanoparticles with CD133 aptamers for targeted
708 delivery of all-trans retinoic acid to osteosarcoma initiating cells. *Biomed Pharmacother*
709 2019;111:751-764. [PMID: 30612000 DOI: 10.1016/j.biopha.2018.11.118]
- 710 [135] Chen F, Zeng Y, Qi X, et al. Targeted salinomycin delivery with EGFR and CD133 aptamers based
711 dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells.
712 *Nanomedicine* 2018;14(7):2115-2127. [PMID: 29898423 DOI: 10.1016/j.nano.2018.05.015]
- 713 [136] Gambera S, Abarrategi A, González-Camacho F, Morales-Molina A, et al. Clonal dynamics in
714 osteosarcoma defined by RGB marking. *Nat Commun* 2018;9(1):3994. [PMID: 30266933 DOI:
715 10.1038/s41467-018-06401-z]
- 716 [137] Tellez-Gabriel M, Cochonneau D, Cadé M, et al. Circulating tumor cell-derived pre-clinical models
717 for personalized medicine. *Cancers (Basel)* 2018;11(1):19. [PMID: 30586936 DOI:
718 10.3390/cancers11010019]

- 719 [138] Zhang W, Zhao JM, Lin J, et al. Adaptive fibrogenic reprogramming of osteosarcoma stem cells
720 promotes metastatic growth. *Cell Rep* 2018;24(5):1266-1277.e5. [PMID: 30067981 DOI:
721 10.1016/j.celrep.2018.06.103]
- 722 [139] Heymann MF, Lézot F, Heymann D. The contribution of immune infiltrates and the local
723 microenvironment in the pathogenesis of osteosarcoma. *Cell Immunol.* 2019;343:103711. [PMID:
724 29117898 DOI: 10.1016/j.cellimm.2017.10.011. 28].
- 725 [140] Avnet S, Lemma S, Cortini M, et al. The release of inflammatory mediators from acidosis-stimulated
726 stromal cells favours tumours invasiveness and metastasis in osteosarcoma. *Cancers (Basel)* 2021
727 22;13(22):5855. [PMID: 34831016 DOI: 10.3390/cancers13225855]
- 728 [141] Avnet S, Lemma S, Cortini M, Di Pompo G, Perut F, Baldini N. Pre-clinical models for studying the
729 interaction between mesenchymal stromal cells and cancer cells and the induction of stemness. *Front*
730 *Oncol.* 2019;9:305. [PMID: 31114753 DOI: 10.3389/fonc.2019.00305].
- 731 [142] Bonuccelli G, Avnet S, Grisendi G, et al. Role of mesenchymal stem cells in osteosarcoma and
732 metabolic reprogramming of tumor cells. [*Oncotarget.* 2014;5(17):7575-88. [PMID: 25277190 DOI:
733 10.18632/oncotarget.2243]
- 734 [143] Baglio SR, Lagerweij T, Pérez-Lanzón M, et al. Blocking tumour-educated MSC paracrine activity
735 halts osteosarcoma progression. *Clin Cancer Res.* 2017;23(14):3721-3733. [PMID: 28053020 doi:
736 10.1158/1078-0432].
737
738